NCT07895524
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12
Timeframe: Week 12
Secondary (9)
Number of Participants Who Experience One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Intervention Due to an AE
Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP) at Week 12
Show 4 moreShow less
Change from Baseline in DAS28-CRP
Percentage of Participants Achieving LDA based on DAS28-CRP
Percentage of Participants Achieving Clinical Remission Based on DAS28-CRP
Change From Baseline in the HAQ-DI Score
Arms and interventions
Period 1: MK-8690Experimental
Participant will receive MK-8690 subcutaneous (SC) for 12 weeks
Period 1: PlaceboPlacebo comparator
Participant will receive placebo SC for 12 weeks
Extension PeriodExperimental
After completing Period 1 participants will receive MK-8690 SC for 40 weeks.
Combination products: MK-8690, Placebo
Drugs: Methotrexate (MTX)